Acadia Healthcare (NASDAQ:ACHC) Given New $41.00 Price Target at Guggenheim

Acadia Healthcare (NASDAQ:ACHC) had its price target hoisted by analysts at Guggenheim from $39.00 to $41.00 in a research note issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim‘s target price indicates a potential upside of 12.63% from the stock’s current price.

Other analysts have also issued research reports about the stock. Barclays raised their price target on shares of Acadia Healthcare from $32.00 to $35.00 and gave the company an “equal weight” rating in a research report on Thursday. TD Cowen lifted their price target on Acadia Healthcare from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Acadia Healthcare in a report on Friday. UBS Group increased their price target on Acadia Healthcare from $31.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Finally, Leerink Partners increased their price objective on shares of Acadia Healthcare from $30.00 to $33.00 and gave the company a “market perform” rating in a report on Wednesday, September 23rd. Eight research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $31.77.

Acadia Healthcare Stock Performance

Shares of ACHC traded up $1.61 during mid-day trading on Friday, reaching $36.40. The company had a trading volume of 715,103 shares, compared to its average volume of 2,827,945. The stock has a market capitalization of $3.39 billion, a P/E ratio of -2.89, a PEG ratio of 10.39 and a beta of 0.64. Acadia Healthcare has a 52-week low of $11.43 and a 52-week high of $39.38. The stock has a 50 day moving average of $29.27 and a two-hundred day moving average of $26.03. The company has a quick ratio of 1.57, a current ratio of 1.57 and a debt-to-equity ratio of 1.20.

Acadia Healthcare (NASDAQ:ACHC) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Acadia Healthcare had a positive return on equity of 6.58% and a negative net margin of 33.07%. The company had revenue of $895.31 million during the quarter, compared to the consensus estimate of $877.76 million. During the same period in the previous year, the company posted $0.72 earnings per share. Acadia Healthcare’s revenue for the quarter was up 5.1% on a year-over-year basis. On average, analysts expect that Acadia Healthcare will post 1.55 earnings per share for the current year.

Institutional Trading of Acadia Healthcare

Several institutional investors have recently made changes to their positions in ACHC. Pinnacle Wealth Planning Services Inc. grew its stake in shares of Acadia Healthcare by 20.7% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 3,209 shares of the company’s stock valued at $88,000 after buying an additional 550 shares in the last quarter. Allworth Financial LP purchased a new stake in shares of Acadia Healthcare in the 2nd quarter valued at $45,000. Global Retirement Partners LLC acquired a new position in Acadia Healthcare during the 2nd quarter worth about $68,000. Integrated Wealth Concepts LLC acquired a new position in Acadia Healthcare during the 2nd quarter worth about $79,000. Finally, Quantbot Technologies LP purchased a new position in Acadia Healthcare during the 2nd quarter valued at about $88,000.

Acadia Healthcare News Summary

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Acadia reported Q3 revenue of $895.3 million, up 5.1% year over year and ahead of estimates, while EPS of $0.60 beat the $0.46 consensus. The company also raised its 2026 financial guidance, a key positive signal for expected performance. Acadia Healthcare Q3 results and guidance
• Positive Sentiment: RBC raised its price target to $41 from $31 and maintained an Outperform rating, signaling increased confidence in the shares. RBC price target update
• Neutral Sentiment: Cantor Fitzgerald lifted its target to $39 but kept a Neutral rating; Barclays raised its target to $35 while maintaining Equal Weight. The higher targets are supportive, but both firms stopped short of a bullish rating. Cantor Fitzgerald rating Barclays rating
• Negative Sentiment: Despite the earnings beat, EPS declined from $0.72 a year earlier to $0.60, tempering the positive results. Q3 earnings comparison

About Acadia Healthcare

Acadia Healthcare Company, Inc is a provider of behavioral healthcare services headquartered in Franklin, Tennessee. The company operates psychiatric hospitals, specialty treatment facilities and outpatient programs focused on mental health and substance use disorders.

Acadia’s services include inpatient and outpatient psychiatric care, addiction treatment, residential treatment, eating-disorder programs, and services for children and adolescents. Its facilities serve patients with a range of behavioral health conditions, including depression, anxiety, trauma-related disorders and substance use disorders.

Founded in 2005, Acadia operates primarily in the United States and also has a significant presence in the United Kingdom through its ownership of Priory, a behavioral healthcare provider.